Valneva (NASDAQ:VALN) Shares Gap Down – What’s Next?

Valneva SE (NASDAQ:VALN) gapped down before the market opened on Wednesday . The stock had previously closed at $6.98, but opened at $6.81. Valneva shares last traded at $6.95, with a volume of 12,500 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Valneva in a report on Friday, February 28th.

Valneva Stock Up 2.4 %

The company has a market cap of $563.95 million, a P/E ratio of -53.38 and a beta of 1.93. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a fifty day moving average of $6.19 and a 200 day moving average of $5.59.

Institutional Investors Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA bought a new stake in shares of Valneva SE (NASDAQ:VALN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.